Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans
暂无分享,去创建一个
S. Taylor-Robinson | Shahid A. Khan | J. Nicholson | E. Holmes | M. Thursz | A. Wijeyesekera | A. Dona | M. Lemoine | R. Njie | A. Thillainayagam | D. Garside | M. Crossey | M. Taal | Y. Shimakawa | B. Kasstan | N. Ladep | H. Njai | E. Okeke | J. Chetwood | E. Banwat | M. Lewis | M. Duguru | H. Fye | Nimzing G. Ladep | Mary M.E. Crossey | Harr F. Njai | Haddy K.S. Fye | Deborah A. Garside | Andrew V. Thillainayagam
[1] N. Chavez-Tapia,et al. Clinical practice guidelines: Management of Hepatocellular Carcinoma , 2014 .
[2] J. Suo,et al. The endothelial lipase protein is promising urinary biomarker for diagnosis of gastric cancer , 2013, Diagnostic Pathology.
[3] Hui Sun,et al. Urinary metabolic profiling identifies a key role for glycocholic acid in human liver cancer by ultra-performance liquid-chromatography coupled with high-definition mass spectrometry. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[4] Ara W. Darzi,et al. Metabolic phenotyping in clinical and surgical environments , 2012, Nature.
[5] F. Sotgia,et al. Ketone body utilization drives tumor growth and metastasis , 2012, Cell cycle.
[6] Xin Lu,et al. Analysis of urinary metabolic signatures of early hepatocellular carcinoma recurrence after surgical removal using gas chromatography-mass spectrometry. , 2012, Journal of proteome research.
[7] P. Ward,et al. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. , 2012, Cancer cell.
[8] J. Lindon,et al. Stability and robustness of human metabolic phenotypes in response to sequential food challenges. , 2012, Journal of proteome research.
[9] V. Mazzaferro,et al. EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma European Association for the Study of the Liver ⇑ , European Organisation for Research and Treatment of Cancer , 2012 .
[10] S. Doniņa,et al. Urinary concentrations of human epidydimis secretory protein 4 (He4) in the diagnosis of ovarian cancer: a case--control study. , 2012, Asian Pacific journal of cancer prevention : APJCP.
[11] R. Franklin,et al. The genetic/metabolic transformation concept of carcinogenesis , 2012, Cancer and Metastasis Reviews.
[12] Z. Bhujwalla,et al. Choline metabolism in malignant transformation , 2011, Nature Reviews Cancer.
[13] Yongzhang,et al. Serum metabolomics reveals the deregulation of fatty acids metabolism in hepatocellular carcinoma and chronic liver diseases , 2011 .
[14] Zhi Chen,et al. Revised Papers , 2022 .
[15] Ping Liu,et al. Serum and Urine Metabolite Profiling Reveals Potential Biomarkers of Human Hepatocellular Carcinoma* , 2011, Molecular & Cellular Proteomics.
[16] Lanjuan Li,et al. Fecal metabolome profiling of liver cirrhosis and hepatocellular carcinoma patients by ultra performance liquid chromatography-mass spectrometry. , 2011, Analytica chimica acta.
[17] H. Thomas,et al. Urinary metabolic biomarkers of hepatocellular carcinoma in an Egyptian population: a validation study. , 2011, Journal of proteome research.
[18] J. Bruix,et al. Management of hepatocellular carcinoma: An update , 2011, Hepatology.
[19] A. Jemal,et al. Global Cancer Statistics , 2011 .
[20] P. Malfertheiner,et al. World Gastroenterology Organisation Guideline. Hepatocellular carcinoma (HCC): a global perspective. , 2010, Journal of gastrointestinal and liver diseases : JGLD.
[21] H. Thomas,et al. Characterization of urinary biomarkers of hepatocellular carcinoma using magnetic resonance spectroscopy in a Nigerian population. , 2010, Journal of proteome research.
[22] T. Manini,et al. Sarcopenia: Clinical evaluation, biological markers and other evaluation tools , 2009, The journal of nutrition, health & aging.
[23] Tao-Tao Liu,et al. Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. , 2009, Analytica chimica acta.
[24] Xin Lu,et al. A metabonomic study of hepatitis B-induced liver cirrhosis and hepatocellular carcinoma by using RP-LC and HILIC coupled with mass spectrometry. , 2009, Molecular bioSystems.
[25] T. Ebbels,et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts , 2007, Nature Protocols.
[26] H. El‐Serag. Epidemiology of hepatocellular carcinoma in USA , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.
[27] Yong Yue,et al. Metabonomic studies of human hepatocellular carcinoma using high-resolution magic-angle spinning 1H NMR spectroscopy in conjunction with multivariate data analysis. , 2007, Journal of proteome research.
[28] H. El‐Serag,et al. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. , 2007, Gastroenterology.
[29] N. Anderson,et al. A List of Candidate Cancer Biomarkers for Targeted Proteomics , 2006, Biomarker insights.
[30] D. Parkin,et al. The global health burden of infection‐associated cancers in the year 2002 , 2006, International journal of cancer.
[31] Henrik Antti,et al. Comparative metabonomics of differential hydrazine toxicity in the rat and mouse. , 2005, Toxicology and applied pharmacology.
[32] J. Ferlay,et al. Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.
[33] D. Gauguier,et al. Statistical total correlation spectroscopy: an exploratory approach for latent biomarker identification from metabolic 1H NMR data sets. , 2005, Analytical chemistry.
[34] B. Daniele,et al. α-fetoprotein and ultrasonography screening for hepatocellular carcinoma , 2004 .
[35] H. El‐Serag,et al. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. , 2004, Gastroenterology.
[36] B. Daniele,et al. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. , 2004, Gastroenterology.
[37] H. Thomas,et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. , 2002, Journal of hepatology.
[38] J. Bruix,et al. Prognosis of Hepatocellular Carcinoma: The BCLC Staging Classification , 1999, Seminars in liver disease.
[39] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[40] Jimmy D Bell,et al. Metabolic changes underlying 31P MR spectral alterations in human hepatic tumours , 1998, NMR in biomedicine.
[41] M. Spraul,et al. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. , 1995, Analytical chemistry.